CSL Ltd Annual Report 2020

More on CSL.com (Investors > Financial Results and Information) Our response to COVID-19 Our Efforts • Playing a leading role in the launch of the CoVIg-19 Plasma Alliance, an unprecedented industry partnership to develop a potential plasma-derived hyperimmune therapy for treating COVID-19. The Alliance also supports national governments in their efforts to fight the pandemic. • Pursing the development of an anti-SARS-CoV-2 plasma product for the Australian market with the potential to treat people with serious complications of COVID-19. • Partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Queensland to accelerate the development, manufacture and distribution of a COVID-19 vaccine candidate which uses Seqirus’ well-established MF59 ® adjuvant technology. • Collaborating with SAB Biotherapeutics, a clinical-stage biopharmaceutical company, to manufacture a novel immunotherapy targeting COVID-19. The potential therapy would be produced without the need for blood plasma donations from recovered COVID-19 patients. • Engaging with investigators regarding the company’s monoclonal antibodies, including CSL312 and CSL324, to identify treatment candidates from the portfolio that have the potential to treat diffuse alveolar damage – one of the devastating respiratory consequences of COVID-19. • Provisioning Seqirus MF59 adjuvant technology to multiple preclinical projects. Our People • Strongly encouraging employees who are able to work from home to do so in accordance with guidance from national and local authorities. • Implementing enhanced measures, including vigorous cleaning efforts and increased social distancing to protect employees at our manufacturing sites, plasma centres and other essential locations. • Offering employees at essential sites flexible Caregiver Leave of Absence and Caregiver Allowance plans to provide support for balancing work with homeschooling and other caregiving responsibilities. • Providing employees at essential sites with all of the PPE needed to perform their job safely and effectively. • Restricting travel to essential trips only to protect employees and prevent the potential spread of COVID-19. Our Patients and Products • Committing to keep plasma centres and manufacturing sites open during the pandemic to maintain supply of lifesaving medicines and influenza vaccines. • Maintaining constant communication with patient advocacy groups to provide updates on the continued safety and availability of our plasma-derived products for those living with rare and serious conditions. See page 38 for more on how CSL’s manufacturing processes handle COVID-19. • Providing essential information for patients in the areas we treat on how COVID-19 may specifically affect them through the Vita news hub of CSLBehring.com. • Continuing much of our work on clinical trials for new potential products and therapies despite a pause in new enrolments at some sites. • Working with our public health partners to plan for the forthcoming influenza season, meeting increased demand for influenza vaccines around the world, to help reduce the burden of influenza on precious health care systems. Our Donors • CSL Plasma implemented a COVID-19 Infectious Disease Response Plan in combination with the CDC’s Exposure Control Plan. The plan includes ensuring the safety of our donors and employees by instituting social distancing, providing masks for donors and enhanced personal protective equipment (PPE) for employees at all plasma centres. • Working closely with local and national authorities to ensure that plasma centres remain open as an essential service during lockdown measures. • Launching a comprehensive communications campaign to raise awareness of the opportunity and need for plasma donation. • Providing donors with an opportunity to give back to their communities through the #CSLPlasmaChallenge. The social media campaign raised money for local healthcare workers, including those on the frontlines of the COVID-19 response. CSL Limited Annual Report 2020 4 Chairman and CEO Message 1